A drug being developed by Trius Therapeutics to combat the antibiotic resistant "superbug" MRSA met its safety and efficacy goals in a mid-stage Phase 2 clinical trial, the company said June 8...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $129